MAPT and Alzheimer disease: Alternatively, streptozotocin, an alkylating agent, was also used to model AD processes in mice and rats [64], inducing neuronal damage, tau hyperphosphorylation, reduced cholinergic conductance, and Aβ peptide-like aggregates.